Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) closed Tuesday at $5.64 per share, down from $5.78 a day earlier. While Vanda Pharmaceuticals Inc. has underperformed by -2.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VNDA fell by -47.68%, with highs and lows ranging from $11.10 to $5.58, whereas the simple moving average fell by -24.94% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On February 25, 2022, Jefferies Downgraded Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) to Hold.
Analysis of Vanda Pharmaceuticals Inc. (VNDA)
Further, the quarter-over-quarter increase in sales is 3.80%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Vanda Pharmaceuticals Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 1.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and VNDA is recording an average volume of 584.85K. On a monthly basis, the volatility of the stock is set at 4.06%, whereas on a weekly basis, it is put at 6.29%, with a loss of -11.88% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.00, showing growth from the present price of $5.64, which can serve as yet another indication of whether VNDA is worth investing in or should be passed over.
How Do You Analyze Vanda Pharmaceuticals Inc. Shares?
Vanda Pharmaceuticals Inc. (VNDA) is based in the USA and is one of the most prominent companies operating in the Biotechnology market. When comparing Vanda Pharmaceuticals Inc. shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 21.95, there is a growth in quarterly earnings of 149.40%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.40%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 104.51% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in VNDA shares?
The recent increase in stakes in VNDA appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in VNDA has decreased by -2.50% in the first quarter. The company now owns 9,243,083 shares of the stock, with a value of $60.91 million, following the sale of -236,907 additional shares during the last quarter. SSgA Funds Management, Inc. made another increased to its shares in VNDA during the first quarter, upping its stake by 22.11%. During the last quarter, the company picked up 824,114 additional shares for a total stake of worth $30.0 million, bringing number of shares owned by the company to 4,551,912.
During the first quarter, The Vanguard Group, Inc. added a 98,558 position in VNDA. Renaissance Technologies LLC purchased an additional 45800.0 shares in the last quarter, increasing its holdings by 1.59%, now holding 2.94 million shares worth $19.34 million. At the end of the first quarter, Dimensional Fund Advisors LP decreased its VNDA holdings by -2.46% and now holds 2.78 million VNDA shares valued at $18.34 million with the lessened 70142.0 shares during the period. VNDA shares are owned by institutional investors to the tune of 104.51% at present.
